BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 17659757)

  • 1. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
    Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
    Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis.
    Daleboudt GM; Berger SP; Broadbent E; Kaptein AA
    Psychol Health Med; 2011 Aug; 16(4):393-404. PubMed ID: 21749237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
    Grootscholten C; Dieker JW; McGrath FD; Roos A; Derksen RH; van der Vlag J; Daha MR; Berden JH
    Ann Rheum Dis; 2007 May; 66(5):693-6. PubMed ID: 17135217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden.
    Söderlin MK; Kautiainen H; Skogh T; Leirisalo-Repo M
    J Rheumatol; 2004 Sep; 31(9):1717-22. PubMed ID: 15338489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing change in health-related quality of life after liver transplantation.
    Estraviz B; Quintana JM; Valdivieso A; Bilbao A; Padierna A; de Urbina JO; Sarabia S
    Clin Transplant; 2007; 21(4):481-99. PubMed ID: 17645707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.